123 related articles for article (PubMed ID: 30974480)
1. Killer-cell immunoglobulin-like receptor ligand mismatch cord blood transplantation in high-risk neuroblastoma.
Matsuno R; Toyama D; Akiyama K; Isoyama K; Shiozawa E; Yamamoto S
Pediatr Int; 2019 Jun; 61(6):566-571. PubMed ID: 30974480
[TBL] [Abstract][Full Text] [Related]
2. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
Fukuda M; Miyajima Y; Miyashita Y; Horibe K
J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma: treatment outcome after incomplete resection of primary tumors.
Moon SB; Park KW; Jung SE; Youn WJ
Pediatr Surg Int; 2009 Sep; 25(9):789-93. PubMed ID: 19629500
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of high-dose
Lee JW; Kang ES; Sung KW; Yi E; Lee SH; Yoo KH; Koo HH
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 28012219
[TBL] [Abstract][Full Text] [Related]
5. Autologous cord blood transplantation in a child with stage 4 neuroblastoma.
Wu KH; Wang SM; Wu HP; Weng T; Peng CT; Chao YH
Bone Marrow Transplant; 2013 Feb; 48(2):317-8. PubMed ID: 22858506
[No Abstract] [Full Text] [Related]
6. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
Caruso DA; Orme LM; Amor GM; Neale AM; Radcliff FJ; Downie P; Tang ML; Ashley DM
Cancer; 2005 Mar; 103(6):1280-91. PubMed ID: 15693021
[TBL] [Abstract][Full Text] [Related]
7. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.
Kushner BH; O'Reilly RJ; Mandell LR; Gulati SC; LaQuaglia M; Cheung NK
J Clin Oncol; 1991 Feb; 9(2):274-9. PubMed ID: 1899111
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous peripheral blood stem cell transplantation, and 13-cis-retinoic acid].
Tang SQ; Huang DS; Wang JW; Zhang XF; Liu LZ; Yu F; Yang G
Zhonghua Er Ke Za Zhi; 2004 Jul; 42(7):486-9. PubMed ID: 15324562
[TBL] [Abstract][Full Text] [Related]
11. Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN.
Goi K; Inukai T; Honna H; Akahane K; Hirose K; Kuroda I; Hasuda N; Koshizuka K; Takano K; Sugita K
Bone Marrow Transplant; 2011 Jun; 46(6):835-9. PubMed ID: 20697365
[TBL] [Abstract][Full Text] [Related]
12. The strategy to treat disseminated neuroblastoma utilizing bone marrow transplantation: what is the surgeon's role?
Yokoyama S; Hirakawa H; Soeda J; Ueno S; Tajima T; Mitomi T; Yabe H; Yabe M; Kato S
Surg Today; 1994; 24(10):895-9. PubMed ID: 7894187
[TBL] [Abstract][Full Text] [Related]
13. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant.
Mugishima H; Harada K; Suzuki T; Chin M; Shimada T; Takamura M; Shichino H; Fujisawa T; Ichikawa M; Iwata M
Acta Paediatr Jpn; 1995 Aug; 37(4):493-9. PubMed ID: 7572151
[TBL] [Abstract][Full Text] [Related]
15. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
[TBL] [Abstract][Full Text] [Related]
16. Value of surgical resection in children with high-risk neuroblastoma.
Englum BR; Rialon KL; Speicher PJ; Gulack B; Driscoll TA; Kreissman SG; Rice HE
Pediatr Blood Cancer; 2015 Sep; 62(9):1529-35. PubMed ID: 25810376
[TBL] [Abstract][Full Text] [Related]
17. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?
Willemze R; Ruggeri A; Purtill D; Rodrigues CA; Gluckman E; Rocha V;
Best Pract Res Clin Haematol; 2010 Jun; 23(2):283-90. PubMed ID: 20837340
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
19. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.
Illhardt T; Toporski J; Feuchtinger T; Turkiewicz D; Teltschik HM; Ebinger M; Schwarze CP; Holzer U; Lode HN; Albert MH; Gruhn B; Urban C; Dykes JH; Teuffel O; Schumm M; Handgretinger R; Lang P
Biol Blood Marrow Transplant; 2018 May; 24(5):1005-1012. PubMed ID: 29307718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
